Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-cd9895bd7-q99xh Total loading time: 0 Render date: 2024-12-22T20:28:11.308Z Has data issue: false hasContentIssue false

Chapter 11 - Myeloid/Lymphoid Neoplasms with Eosinophilia and Gene Rearrangement

from Section IV - Neoplastic Disorders of Bone Marrow

Published online by Cambridge University Press:  25 January 2024

By
Bradford Siegele
Edited by
Xiayuan Liang ,
Bradford Siegele  and
Jennifer Picarsic
Xiayuan Liang
Affiliation:
Children’s Hospital of Colorado
Bradford Siegele
Affiliation:
Children’s Hospital of Colorado
Jennifer Picarsic
Affiliation:
Cincinnati Childrens Hospital Medicine Center
Get access

Summary

Myeloid/lymphoid neoplasms with eosinophilia and gene rearrangement are clonal neoplasms with characteristically prominent eosinophilic proliferation and defining cytogenetic rearrangements. (See Table 11.1.)

Type
Chapter
Information
Pediatric Pathology of Hematopoietic and Histiocytic Disorders , pp. 126 - 129
Publisher: Cambridge University Press
Print publication year: 2024

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Swerdlow, S, Campo, E, Harris, N, et al., eds. WHO classification of tumors of haematopoietic and lymphoid tissues. Rev. 4th ed. IARC Press; 2017.Google Scholar
Klion, AD, Robyn, J, Akin, C, et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood. 2004;103(2):473–8. doi: 10.1182/blood-2003-08-2798Google Scholar
Dalal, BI, Horsman, DE, Bruyèrè, H, et al. Imatinib mesylate responsiveness in aggressive systemic mastocytosis: novel association with a platelet derived growth factor receptor beta mutation. Am J Hematol. 2007;82(1):77–9. doi: 10.1002/ajh.20833Google Scholar
Bain, BJ, Fletcher, SH. Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome. Immunol Allergy Clin North Am. 2007;27(3):377–88. doi: 10.1016/j.iac.2007.06.001CrossRefGoogle ScholarPubMed
Vandenberghe, P, Wlodarska, I, Michaux, L, et al. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia. 2004;18(4):734–42. doi: 10.1038/sj.leu.2403313CrossRefGoogle ScholarPubMed
Naymagon, L, Marcellino, B, Mascarenhas, J. Eosinophilia in acute myeloid leukemia: Overlooked and underexamined. Blood Rev. 2019;36:23–31. doi: 10.1016/j.blre.2019.03.007Google Scholar
Fournier, B, Balducci, E, Duployez, N, et al. B-ALL with t(5;14)(q31;q32). Front Oncol. 2019;9:1374. doi: 10.3389/fonc.2019.01374CrossRefGoogle Scholar
Klion, AD, Law, MA, Riemenschneider, W, et al. Familial eosinophilia: a benign disorder? Blood. 2004;103(11):4050–5. doi: 10.1182/blood-2003-11-3850Google Scholar
Reiter, A, Gotlib, J. Myeloid neoplasms with eosinophilia. Blood. 2017;129(6):704–714. doi: 10.1182/blood-2016-10-695973Google Scholar
Rumi, E, Milosevic, JD, Selleslag, D, et al. Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene. Ann Hematol. 2015;94(11):1927–8. doi: 10.1007/s00277-015-2451-7CrossRefGoogle ScholarPubMed
Lierman, E, Selleslag, D, Smits, S, et al. Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia. Blood. 2012;120(7):1529–31. doi: 10.1182/blood-2012-06-433821Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×